Q-omics provides the consensus-scored RPP14 profile across patient tissues and cancer cell-line models. RPP14 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPP14 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPP14 RNA expression shows 20,363 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where RPP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPP14 survival associations across molecular data types. RPP14 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPP14 RNA expression–survival associations across cancer types. High RPP14 expression shows unfavorable associations in ACC and CESC, but favorable associations in KIRC, READ, COAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPP14 RNA expression.
This table summarizes RPP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RPP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPP14 shows lower tumor expression in KIRC, THCA, KIRP, HNSC and BRCA and higher tumor expression in LIHC. The KIRC box plot shows higher RPP14 RNA expression in normal versus tumor tissue (log2 FC = −0.529, t-test p < 0.001).
This table shows molecular features associated with RPP14 in patient tissues and cancer cell lines. In patient samples, RPP14 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPP14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
